Danish diabetes technology company Hedia will implement a leadership change effective December 1, 2025, when Rasmus Kofoed will assume the role of CEO. He succeeds Lars Christian Lund, who, after approximately two years in the position, has decided to step down to become Group CEO at another international company.
Hedia develops digital solutions that help people with insulin-dependent diabetes better understand and manage their treatment using data, artificial intelligence, and intuitive app technology. Founded in 2016, the company has established itself as a leading European player in digital diabetes management and digital therapeutics.
Carl Bilbo, Chairman of the Board of Directors of Hedia, commented: “Under Lars Christian Lund’s leadership, Hedia has evolved from an ambitious startup to a professionally scalable company with a strong regulatory and commercial track record. Lars has played a pivotal role in strengthening the organization, achieving MDR approval, and laying the foundation for global growth. On behalf of the Board of Directors, I would like to thank him for his outstanding contribution and dedication. We are equally pleased to welcome Rasmus Kofoed as our new CEO. Rasmus brings a strong strategic and commercial background with proven experience in life sciences and medical technology. He is the ideal person to lead Hedia into the next phase.”
Also Read: Paradromics Gets FDA Nod for Connect-One Clinical Study
Rasmus Kofoed brings a strong track record in the life sciences and medical technology sectors. He has held senior management positions at Novo Nordisk, Abbott, Roche, and Medtronic, and was CEO of ChemoMetec, with overall commercial and strategic responsibility, including growth, transformation, and international expansion. With this solid commercial experience, he will assume the role of CEO on December 1, 2025, with the ambition of further strengthening Hedia’s product and market platform and expanding the company’s international partnerships.
“I see enormous potential in Hedia,” Rasmus Kofoed stated.
“The company combines clinical expertise with technology in a way that creates real value for people with diabetes. I look forward to working with the team to expand our reach, strengthen our partnerships, and continue on the path to making Hedia a leading player in digital diabetes care.”
Source: PRNewswire